Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Gamida Cell stock

GMDAQ
IL0011552663
A2N7XM

Price

0
Today +/-
-0
Today %
-0 %
P

Gamida Cell stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Gamida Cell stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Gamida Cell stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Gamida Cell stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Gamida Cell's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Gamida Cell Stock Price History

DateGamida Cell Price
5/24/20240 undefined
5/23/20240 undefined

Gamida Cell Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Gamida Cell, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Gamida Cell from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Gamida Cell’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Gamida Cell. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Gamida Cell’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Gamida Cell’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Gamida Cell’s growth potential.

Gamida Cell Revenue, EBIT and net profit per share

DateGamida Cell RevenueGamida Cell EBITGamida Cell Net Income
2025e0 undefined0 undefined0 undefined
2024e0 undefined0 undefined0 undefined
20230 undefined0 undefined0 undefined
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined

Gamida Cell Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2021202220232024e2025e
00116190
---1,500.001,087.50
-----
00000
-87-74-72-7236
---7,200.00-450.0018.95
-89-79-62-9026
--11.24-21.5245.16-128.89
59.2563.83110.0500
-----
Details

Keystats

ⓘ

Revenue and Growth

The Gamida Cell Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Gamida Cell is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201920202021
     
55.4127.1795.93
000
000
000
1.313.092.69
56.7130.2698.61
11.4325.0842.42
000
000
000
000
0.642.987.76
12.0728.0650.17
68.77158.31148.79
     
92166169
238.99376.37381.23
-204.1-247.66-337.46
000
000
34.98128.8743.94
6.0814.1415.96
5.317.369.48
000
000
000
11.421.525.43
0071.42
000
22.47.948
22.47.9479.42
33.7929.44104.85
68.78158.31148.79
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Gamida Cell provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Gamida Cell's financial health and stability.

Assets

Gamida Cell's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Gamida Cell must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Gamida Cell after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Gamida Cell's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)

Gamida Cell stock margins

The Gamida Cell margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Gamida Cell. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Gamida Cell.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Gamida Cell's sales revenue. A higher gross margin percentage indicates that the Gamida Cell retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Gamida Cell's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Gamida Cell's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Gamida Cell's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Gamida Cell. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Gamida Cell's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Gamida Cell Margin History

Gamida Cell Gross marginGamida Cell Profit marginGamida Cell EBIT marginGamida Cell Profit margin
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %

Gamida Cell Stock Sales Revenue, EBIT, Earnings per Share

The Gamida Cell earnings per share therefore indicates how much revenue Gamida Cell has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Gamida Cell earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Gamida Cell's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Gamida Cell’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Gamida Cell's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Gamida Cell Revenue, EBIT and net profit per share

DateGamida Cell Sales per ShareGamida Cell EBIT per shareGamida Cell Earnings per Share
2025e0 undefined0 undefined0 undefined
2024e0 undefined0 undefined0 undefined
20230 undefined0 undefined0 undefined
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined

Gamida Cell business model

The company Gamida Cell Ltd was founded in 1998 in Jerusalem, Israel and is involved in the development and manufacture of cell therapy products for various diseases. The company has had an exciting history since its inception, including a number of successes and milestones. Gamida Cell's business model is based on the production of cell therapy products for patients suffering from severe diseases. These include blood diseases such as leukemia, lymphoma, or sickle cell anemia. The company uses a unique technology platform called "NiCord," which allows for the extraction and expansion of cells from umbilical cord blood to provide a larger number of cells for transplantation. This platform offers a way to overcome some of the limitations and challenges associated with the use of bone marrow or stem cell donors. Gamida Cell has made significant progress in the development of cell therapy products in recent years. The company is currently working on the development of therapies for various indications such as blood diseases, solid tumors, and autoimmune diseases. Another goal of Gamida Cell is to use its technology platform for the development of drugs for other indications. The company has various divisions in which it operates. The primary division is research and development of cell therapies. However, the company also has a manufacturing facility for the production of its products and a clinical studies department responsible for conducting studies and tests of therapeutics. Gamida Cell collaborates closely with research institutions and other companies in the biotechnology industry to further develop its technology platform and advance the progress of cell therapies overall. Gamida Cell currently offers a range of products, starting with its flagship product "NiCord." NiCord is a cell therapy made from umbilical cord blood cells and can be used for transplantation in patients with blood diseases such as leukemia or lymphoma. The company is also working on the development of additional products, including a cell therapy for solid tumors and a treatment for autoimmune diseases. In recent years, Gamida Cell has received several awards and recognitions. The company has attracted several leading scientists and researchers who collaborate closely with Gamida Cell to further develop the company's technology platform and create new therapies. At the same time, Gamida Cell has also carried out several capital increases to advance research and product development. Overall, Gamida Cell has an excellent reputation in the biotech industry. The company has shown that it can play a leading role in the development of cell therapies that can improve the lives of patients with severe diseases. With the growing demand for new treatment options and the rapid progress in the field of biotech, Gamida Cell is well positioned to continue expanding and developing new therapies that have the potential to change the lives of millions of people worldwide. Gamida Cell is one of the most popular companies on Eulerpool.com.

Gamida Cell SWOT Analysis

Strengths

1. Innovative Technology: Gamida Cell Ltd is known for its cutting-edge technology in cell therapy, which provides a competitive advantage in the market.

2. Strong Research and Development: The company has a robust R&D department that constantly strives to develop new and improved treatments, enhancing its product portfolio.

3. Strategic Partnerships: Gamida Cell maintains collaborations with key industry players, allowing access to additional resources, expertise, and potential distribution channels.

Weaknesses

1. Limited Market Presence: Despite its innovative technology, Gamida Cell faces challenges in establishing a strong market presence due to intense competition and regulatory barriers.

2. Financial Dependency: The company heavily relies on external funding to support its operations, which can pose risks during economic downturns or fluctuating investor confidence.

3. Scale and Production Capacity: Gamida Cell's limited scale and production capacity could potentially hinder its ability to meet market demand effectively, delaying growth opportunities.

Opportunities

1. Expanding Cell Therapy Market: With the increasing demand for advanced medical treatments, Gamida Cell has the opportunity to capitalize on the growing cell therapy market.

2. Regulatory Advancements: Regulatory bodies worldwide are becoming more supportive of cell therapy, creating favorable conditions for Gamida Cell to obtain necessary approvals with relative ease.

3. Strategic Partnerships: Collaborating with pharmaceutical companies or research institutions could enable Gamida Cell to broaden its product pipeline and access new markets or patient populations.

Threats

1. Competitive Landscape: Gamida Cell operates in a highly competitive industry with numerous established players vying for market share, intensifying the threat of competition.

2. Regulatory Challenges: The evolving and stringent regulatory frameworks governing cell therapy can result in delays or increased costs associated with gaining necessary approvals for Gamida Cell's products.

3. Technological Advancements: Competitors' advancements in cell therapy or alternative medical treatment options could potentially render Gamida Cell's technology outdated or less attractive to customers.

Gamida Cell Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Gamida Cell historical P/E ratio, EBIT multiple, and P/S ratio

Gamida Cell shares outstanding

The number of shares was Gamida Cell in 2023 — This indicates how many shares 110.05 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Gamida Cell earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Gamida Cell's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Gamida Cell’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Gamida Cell's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

The World’s Best Investors Are On Eulerpool

Unfortunately, there are currently no price targets and forecasts available for Gamida Cell.

Gamida Cell latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/20240 0  (6.54 %)2024 Q1
12/31/20230 0  (74.36 %)2023 Q4
9/30/20230 0  (94.24 %)2023 Q3
6/30/20230 0  (-54.92 %)2023 Q2
3/31/20230 0  (4.39 %)2023 Q1
12/31/20220 0  (-16.5 %)2022 Q4
9/30/20220 0  (7.99 %)2022 Q3
6/30/20220 0  (-3.06 %)2022 Q2
3/31/20220 0  (2.91 %)2022 Q1
12/31/20210 0  (-24.64 %)2021 Q4
1
2
3

Gamida Cell shareholders

%
Name
Stocks
Change
Date
4.94294 % Fidelity Management & Research Company LLC7,614,598012/31/2023
3.35571 % Community US Fund Management Inc5,169,471011/8/2023
2.81516 % Novartis Pharma AG4,336,75905/10/2023
2.43274 % Levin Capital Strategies, L.P.3,747,630-5,380,7463/31/2024
2.37271 % Meitav Dash Investments Ltd.3,655,158012/31/2023
1.67591 % Access Industries Holdings, L.L.C.2,581,746-7,161,11111/20/2023
1.66755 % Millennium Management LLC2,568,8662,568,86612/31/2023
1.43589 % Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD2,211,981012/31/2023
0.89460 % Adams Julian1,378,1271,113,0563/15/2024
0.66418 % Mariner Wealth Advisors1,023,164294,52212/31/2023
1
2
3
4
5
...
10

Most common questions regarding Gamida Cell

What values and corporate philosophy does Gamida Cell represent?

Gamida Cell Ltd is a biotechnology company that specializes in developing cell and gene therapies. The company values innovation, scientific excellence, and a patient-centric approach. Gamida Cell aims to improve the lives of patients with life-threatening diseases by creating potentially curative treatments. The company's corporate philosophy revolves around a commitment to advancing medical science and finding new treatment options for patients in need. Gamida Cell believes in leveraging cutting-edge technology and collaborating with key partners to drive advancements in cellular therapy. Through its dedication to research and development, Gamida Cell seeks to transform the treatment landscape for patients worldwide.

In which countries and regions is Gamida Cell primarily present?

Gamida Cell Ltd is primarily present in the United States, Europe, and Israel.

What significant milestones has the company Gamida Cell achieved?

Gamida Cell Ltd, a renowned biotechnology company, has achieved several significant milestones since its establishment. Notably, the company successfully completed multiple clinical trials for its lead product candidate, omidubicel. Omidubicel is a potential breakthrough treatment for patients in need of hematopoietic stem cell transplantation. Gamida Cell received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for omidubicel, acknowledging its potential to address unmet medical needs. Furthermore, the company successfully raised substantial funds through public offerings, bolstering its financial position and supporting ongoing research and development efforts. With these milestones, Gamida Cell Ltd has positioned itself as a pioneer in the field of cell therapy.

What is the history and background of the company Gamida Cell?

Gamida Cell Ltd is an innovative biotechnology company specializing in the development of cell therapies. Founded in 1998, the company has been at the forefront of cellular and immune therapies, aiming to cure severe and life-threatening diseases, particularly blood cancers and genetic disorders. Gamida Cell's proprietary technology, known as Nicord®, harnesses the power of hematopoietic stem cells, expanded in culture, to provide a reliable and readily available source for bone marrow transplantations. With a strong focus on research and development, Gamida Cell has formed partnerships with leading pharmaceutical companies and received multiple grants, aiming to bring transformative treatments to patients worldwide.

Who are the main competitors of Gamida Cell in the market?

The main competitors of Gamida Cell Ltd in the market are Celgene Corporation, Novartis AG, and bluebird bio Inc.

In which industries is Gamida Cell primarily active?

Gamida Cell Ltd is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Gamida Cell?

The business model of Gamida Cell Ltd focuses on the development and commercialization of innovative cell therapies to treat and cure cancer and rare genetic diseases. Gamida Cell utilizes its proprietary technology platform, NiCord®, to expand umbilical cord blood cells and create therapies that can be readily available for patients in need. By partnering with industry leaders and conducting clinical trials, Gamida Cell aims to deliver effective and accessible treatments to improve the lives of patients worldwide. As a leading biotechnology company, Gamida Cell is committed to advancing the field of cell therapy and bringing hope to patients and their families.

What is the P/E ratio of Gamida Cell 2024?

The P/E ratio cannot be calculated for Gamida Cell at the moment.

What is the P/S ratio of Gamida Cell 2024?

The P/S cannot be calculated for Gamida Cell currently.

What is the Quality Investing of Gamida Cell?

The Quality Investing for Gamida Cell is 2/10.

What is the revenue of Gamida Cell 2024?

The revenue cannot currently be calculated for Gamida Cell.

How high is the profit of Gamida Cell 2024?

The profit cannot currently be calculated for Gamida Cell.

What is the business model of Gamida Cell

Gamida Cell Ltd is a biopharmaceutical company specializing in the development of therapies for the treatment of cancer and rare genetic diseases. The company is divided into several business segments, including research and development, production, and distribution.

What is the Gamida Cell dividend?

Gamida Cell pays a dividend of 0 USD distributed over payouts per year.

How often does Gamida Cell pay dividends?

The dividend cannot currently be calculated for Gamida Cell or the company does not pay out a dividend.

What is the Gamida Cell ISIN?

The ISIN of Gamida Cell is IL0011552663.

What is the Gamida Cell WKN?

The WKN of Gamida Cell is A2N7XM.

What is the Gamida Cell ticker?

The ticker of Gamida Cell is GMDAQ.

How much dividend does Gamida Cell pay?

Over the past 12 months, Gamida Cell paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Gamida Cell is expected to pay a dividend of 0 USD.

What is the dividend yield of Gamida Cell?

The current dividend yield of Gamida Cell is .

When does Gamida Cell pay dividends?

Gamida Cell pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Gamida Cell?

Gamida Cell paid dividends every year for the past 0 years.

What is the dividend of Gamida Cell?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Gamida Cell located?

Gamida Cell is assigned to the 'Health' sector.

Wann musste ich die Aktien von Gamida Cell kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Gamida Cell from 11/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/5/2024.

When did Gamida Cell pay the last dividend?

The last dividend was paid out on 11/5/2024.

What was the dividend of Gamida Cell in the year 2023?

In the year 2023, Gamida Cell distributed 0 USD as dividends.

In which currency does Gamida Cell pay out the dividend?

The dividends of Gamida Cell are distributed in USD.

All fundamentals about Gamida Cell

Our stock analysis for Gamida Cell Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Gamida Cell Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.